Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 1000

Next Previous
Drug Profile

CTX 1000

Alternative Names: AAV9 gene therapy - Celosia Therapeutics; CTX-1000

Latest Information Update: 20 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celosia Therapeutics
  • Class Antidementias; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis
  • Preclinical Frontotemporal dementia

Most Recent Events

  • 20 Feb 2026 Celosia Therapeutics plans to files an IND application for the first in patient trial for Amyotrophic lateral sclerosis (ADNM)
  • 12 Feb 2026 Preclinical trials in Frontotemporal dementia in Australia (Intracisternal) (Celosia Therapeutics pipeline, February 2026)
  • 12 Feb 2026 Prior to February 2026, Celosia Therapeutics plans to files an IND application for the first in patient trial for Amyotrophic lateral sclerosis in third quarter 2025(Celosia Therapeutics pipeline, February 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top